Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,518 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination.
Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Kalikawe R, Datwani S, Waterworth R, Umviligihozo G, Ennis S, Young L, Dong W, Kirkby D, Burns L, Leung V, Holmes DT, DeMarco ML, Simons J, Matic N, Montaner JSG, Brumme CJ, Prystajecky N, Niikura M, Lowe CF, Romney MG, Brockman MA, Brumme ZL. Lapointe HR, et al. Among authors: simons j. Front Immunol. 2022 Sep 6;13:947021. doi: 10.3389/fimmu.2022.947021. eCollection 2022. Front Immunol. 2022. PMID: 36148225 Free PMC article.
Reproducible Research and Reports with R.
Simons JE, Holmes DT. Simons JE, et al. J Appl Lab Med. 2019 Nov;4(3):471-473. doi: 10.1373/jalm.2018.028373. J Appl Lab Med. 2019. PMID: 31659090 No abstract available.
Weak humoral immune reactivity among residents of long-term care facilities following one dose of the BNT162b2 mRNA COVID-19 vaccine.
Brockman MA, Mwimanzi F, Sang Y, Ng K, Agafitei O, Ennis S, Lapointe H, Young L, Umviligihozo G, Burns L, Brumme C, Leung V, Montaner JSG, Holmes D, DeMarco M, Simons J, Niikura M, Pantophlet R, Romney MG, Brumme ZL. Brockman MA, et al. Among authors: simons j. medRxiv [Preprint]. 2021 Mar 24:2021.03.17.21253773. doi: 10.1101/2021.03.17.21253773. medRxiv. 2021. PMID: 33791737 Free PMC article. Preprint.
Repeat virological and serological profiles in hospitalized patients initially tested by nasopharyngeal RT-PCR for SARS-CoV-2.
Reich N, Lowe CF, Puddicombe D, Matic N, Greiner J, Simons J, Leung V, Chu T, Naik H, Myles N, Burns L, Romney MG, Ritchie G, Champagne S, Dooley K, Sekirov I, Stefanovic A. Reich N, et al. Among authors: simons j. J Med Virol. 2021 Dec;93(12):6808-6812. doi: 10.1002/jmv.27227. Epub 2021 Jul 29. J Med Virol. 2021. PMID: 34297350 Free PMC article.
SARS-CoV-2 serology: Validation of high-throughput chemiluminescent immunoassay (CLIA) platforms and a field study in British Columbia.
Sekirov I, Barakauskas VE, Simons J, Cook D, Bates B, Burns L, Masud S, Charles M, McLennan M, Mak A, Chahil N, Vijh R, Hayden A, Goldfarb D, Levett PN, Krajden M, Morshed M. Sekirov I, et al. Among authors: simons j. J Clin Virol. 2021 Sep;142:104914. doi: 10.1016/j.jcv.2021.104914. Epub 2021 Jul 16. J Clin Virol. 2021. PMID: 34304088 Free PMC article.
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy.
Brumme ZL, Mwimanzi F, Lapointe HR, Cheung P, Sang Y, Duncan MC, Yaseen F, Agafitei O, Ennis S, Ng K, Basra S, Lim LY, Kalikawe R, Speckmaier S, Moran-Garcia N, Young L, Ali H, Ganase B, Umviligihozo G, Omondi FH, Atkinson K, Sudderuddin H, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes D, DeMarco ML, Simons J, Hedgcock M, Romney MG, Barrios R, Guillemi S, Brumme CJ, Pantophlet R, Montaner JSG, Niikura M, Harris M, Hull M, Brockman MA. Brumme ZL, et al. Among authors: simons j. medRxiv [Preprint]. 2021 Oct 15:2021.10.03.21264320. doi: 10.1101/2021.10.03.21264320. medRxiv. 2021. Update in: NPJ Vaccines. 2022 Feb 28;7(1):28. doi: 10.1038/s41541-022-00452-6 PMID: 34671779 Free PMC article. Updated. Preprint.
Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults.
Brockman MA, Mwimanzi F, Lapointe HR, Sang Y, Agafitei O, Cheung PK, Ennis S, Ng K, Basra S, Lim LY, Yaseen F, Young L, Umviligihozo G, Omondi FH, Kalikawe R, Burns L, Brumme CJ, Leung V, Montaner JSG, Holmes D, DeMarco ML, Simons J, Pantophlet R, Niikura M, Romney MG, Brumme ZL. Brockman MA, et al. Among authors: simons j. J Infect Dis. 2022 Apr 1;225(7):1129-1140. doi: 10.1093/infdis/jiab592. J Infect Dis. 2022. PMID: 34888688 Free PMC article.
Older Adults Mount Less Durable Humoral Responses to a Two-dose COVID-19 mRNA Vaccine Regimen, but Strong Initial Responses to a Third Dose.
Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, Kalikawe R, Datwani S, Omondi FH, Burns L, Young L, Leung V, Agafitei O, Ennis S, Dong W, Basra S, Lim LY, Ng K, Pantophlet R, Brumme CJ, Montaner JSG, Prystajecky N, Lowe CF, DeMarco ML, Holmes DT, Simons J, Niikura M, Romney MG, Brumme ZL, Brockman MA. Mwimanzi F, et al. Among authors: simons j. medRxiv [Preprint]. 2022 Feb 21:2022.01.06.22268745. doi: 10.1101/2022.01.06.22268745. medRxiv. 2022. Update in: J Infect Dis. 2022 Sep 21;226(6):983-994. doi: 10.1093/infdis/jiac199 PMID: 35018381 Free PMC article. Updated. Preprint.
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy.
Brumme ZL, Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Duncan MC, Yaseen F, Agafitei O, Ennis S, Ng K, Basra S, Lim LY, Kalikawe R, Speckmaier S, Moran-Garcia N, Young L, Ali H, Ganase B, Umviligihozo G, Omondi FH, Atkinson K, Sudderuddin H, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes D, DeMarco ML, Simons J, Hedgcock M, Romney MG, Barrios R, Guillemi S, Brumme CJ, Pantophlet R, Montaner JSG, Niikura M, Harris M, Hull M, Brockman MA. Brumme ZL, et al. Among authors: simons j. NPJ Vaccines. 2022 Feb 28;7(1):28. doi: 10.1038/s41541-022-00452-6. NPJ Vaccines. 2022. PMID: 35228535 Free PMC article.
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses.
Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, Kalikawe R, Speckmaier S, Moran-Garcia N, Datwani S, Duncan MC, Agafitei O, Ennis S, Young L, Ali H, Ganase B, Omondi FH, Dong W, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes D, DeMarco ML, Simons J, Hedgcock M, Prystajecky N, Lowe CF, Pantophlet R, Romney MG, Barrios R, Guillemi S, Brumme CJ, Montaner JSG, Hull M, Harris M, Niikura M, Brockman MA, Brumme ZL. Lapointe HR, et al. Among authors: simons j. medRxiv [Preprint]. 2022 Mar 23:2022.03.22.22272793. doi: 10.1101/2022.03.22.22272793. medRxiv. 2022. Update in: J Infect Dis. 2023 Apr 12;227(7):838-849. doi: 10.1093/infdis/jiac229 PMID: 35350205 Free PMC article. Updated. Preprint.
1,518 results